930768-36-8

Upstream product

• 930768-35-7 ethyl 1-(4-toluenesulfonyl)-1H-pyrazole-4-carboxylate 

Downstream Products

• 916257-05-1 1-(p-tolylsulfonyl)pyrazole-4-carbaldehyde 
• 930768-37-9 4-chloromethyl-1-(toluene-4-sulfonyl)-1H-pyrazole 
• 930768-24-4 methanesulfonic acid 1-(toluene-4-sulfonyl)-1H-pyrazol-4-ylmethyl ester 

Relevant academic research and scientific papers

FUMAGILLOL COMPOUNDS AND METHODS OF MAKING AND USING SAME

Disclosed herein, in part, are fumagillol compounds and methods of use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making fumagillol compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.

AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS

Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are methods of making and methods of using same.

ARYL SUBSTITUTED IMIDAZO [4,5-C] PYRIDINE COMPOUNDS AS C3A RECEPTOR ANTAGONISTS

Aryl substituted imidazo[4,5-c] pyridine compounds of formula (I) or pharmaceutically acceptable salt thereof are provided. These compounds are useful in pharmaceutical compositions as C3a antagonists for treating a variety of medical conditions associated with the Complement cascade.